 |
인쇄하기
취소
|
Choong-wae, Sanwa to develop SK-0403 for treatment of diabetes
Choong-wae Pharm has entered into an exclusive licensing agreement with Sanwa Kagaku Kenkyusho Co., Ltd. (Sanwa) to develop and commercialize SK-0403 (dipeptidyl peptidase-IV inhibitor) for treatment of diabetes, according to a Choong-wae official.
The companies currently estimate Korea's annual diabetic market could be over 350 billion won.
SK-0403, a highly selective DPP-4 inhibitor und...
The companies currently estimate Korea's annual diabetic market could be over 350 billion won.
SK-0403, a highly selective DPP-4 inhibitor und...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.